Health and Fitness Health and Fitness
Wed, December 22, 2010
[ Wed, Dec 22nd 2010 ] - Market Wire
Clinical Data, Inc. Receives Notice of IND Filing .. stone Payment for A2A Agonist Development Program
[ Wed, Dec 22nd 2010 ] - Market Wire
Ligand Earns $1 Million Upfront Payment from Pfizer on Sublicensing of Tanaproget
[ Wed, Dec 22nd 2010 ] - Market Wire
U.S. Physical Therapy Makes Six Clinic Acquisition in Mid-Atlantic
[ Wed, Dec 22nd 2010 ] - Market Wire
CENTRIC HEALTH REPORTS ACQUISITION SUBJECT TO COURT APPROVAL
[ Wed, Dec 22nd 2010 ] - Market Wire
BioCryst Initiates a Phase 2b Study of BCX4208 as .. Gout Patients Not Responding to Allopurinol Alone
[ Wed, Dec 22nd 2010 ] - Market Wire
Aanvraag Biogen Idec en Elan voor aanpassing bijs .. et PML-risico met antilichamen voor anti-JC virus
[ Wed, Dec 22nd 2010 ] - Market Wire
Biogen Idec e Elan chiedono l'aggiornamento dell' .. ludendo lo status dell'anticorpo anti virus JC, c
[ Wed, Dec 22nd 2010 ] - Market Wire
Biogen Idec et Elan d©posent des demandes de mis .. TYSABRI dans le but da?aider stratifier le risque
[ Wed, Dec 22nd 2010 ] - Market Wire
Biogen Idec und Elan stellen Antrge auf Aktualisi .. n fr TYSABRI, die mittels des JC-Virus-Antikrpers
Tue, December 21, 2010
[ Tue, Dec 21st 2010 ] - Market Wire
Biogen Idec and Elan Submit Applications to Updat .. elp Stratify Risk of PML with Anti-JC Virus Antib
[ Tue, Dec 21st 2010 ] - Market Wire
CardioNet, Inc. Completes Acquisition of Biotel Inc.
[ Tue, Dec 21st 2010 ] - Market Wire
American CareSource Holdings Names William J. Simpson, Jr. Chief Operating Officer
[ Tue, Dec 21st 2010 ] - Market Wire
Vertex Provides Update to Ongoing Phase 2 Study E .. aprevir and VX-222 for the Treatment of Hepatitis
[ Tue, Dec 21st 2010 ] - Market Wire
Teva and Takeda Settle Generic ACTOS® and ACTOplus met® Litigation
[ Tue, Dec 21st 2010 ] - Market Wire
Humana Inc. Completes Acquisition of Concentra Inc.
[ Tue, Dec 21st 2010 ] - Market Wire
Enzon Board Authorizes Share Repurchase Program
[ Tue, Dec 21st 2010 ] - Market Wire
Landmark Medtronic CoreValve® U.S. Clinical Trial Begins
[ Tue, Dec 21st 2010 ] - Market Wire
Law Office of Jonathan M. Stein, P.L. Investigate .. y Duty by the Board of Martek Biosciences Corpora
[ Tue, Dec 21st 2010 ] - Market Wire
Kendall Law Group Investigates Martek Biosciences Corporation for Shareholders
[ Tue, Dec 21st 2010 ] - Market Wire
Bernstein Liebhard LLP Announces Investigation of .. uisition of Martek Biosciences Corporation by DSM
[ Tue, Dec 21st 2010 ] - Market Wire
Four Rivers (trading as 'Verta Energy') Receives .. roposed UK Waste-to-Energy Plant to Generate Elec
[ Tue, Dec 21st 2010 ] - Market Wire
Rigrodsky & Long, P.A. Investigates Martek Biosciences Corporation Buyout
[ Tue, Dec 21st 2010 ] - Market Wire
A Letter From the President of Biomagnetics Diagnostics Corp.
[ Tue, Dec 21st 2010 ] - Market Wire
Health Net Federal Services Awarded Department of .. r VA Clinics in Espanola and Las Vegas, New Mexic
[ Tue, Dec 21st 2010 ] - Market Wire
Emeritus Senior Living Receives Best of the Web Award 2011
[ Tue, Dec 21st 2010 ] - Market Wire
Allos Therapeuticsa? Marketing Authorisation Appl .. cepted for Review by European Medicines Agency (E
[ Tue, Dec 21st 2010 ] - Market Wire
IntegraMed® CFO John Hlywak to Retire at Year-End; Appoints Tim Sheehan as Interim-CFO
[ Tue, Dec 21st 2010 ] - Market Wire
Pro-Pharmaceuticals & Mount Sinai School of Medic .. nnounce New Liver Fibrosis Research Collaboration
[ Tue, Dec 21st 2010 ] - Market Wire
Amedisys to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Tue, Dec 21st 2010 ] - Market Wire
Biogen Idec y Neurimmune suscriben acuerdo para tres programas de enfermedades neurodegenerativas

Biogen Idec y Neurimmune suscriben acuerdo para tres programas de enfermedades neurodegenerativas


Published on 2010-12-21 03:41:15 - Market Wire
  Print publication without navigation


WESTON, Massachussets & ZURICH--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) y [ Neurimmune Holding AG ] han comunicado que Biogen Idec ha adquirido una filial de Neurimmune, que incluye los derechos internacionales de tres programas preclnicos de inmunoterapia. Los tres programas estn centrados en el descubrimiento y desarrollo de anticuerpos humanos noveles que abordan tres blancos del sistema nervioso central: alfa-sinuclena, tau y TDP-43. Se piensa que estos blancos pueden influir en el tratamiento y prevencin de una amplia variedad de enfermedades neurodegenerativas, incluida la enfermedad del Parkinson, Alzheimer y esclerosis lateral amiotrfica (ALS en sus siglas en ingl©s). Biogen Idec realizar un pago inicial de $32,5 millones y hasta $395 millones en pagos contingentes.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources